Approval of a second controversial Alzheimer's drug is dividing medical experts

Today's edition: With House lawmakers sworn in, the House Steering Committee will meet to decide the unresolved panel chairs, such as for the House Ways and Means Committee. The future of a new Alzheimer's drug is unclear, even as the Food and Drug Administration granted fast-track approval to the treatment Friday afternoon. For now, Medicare's coverage is…